The Determinants of Fertility Preservation in TRANSgender Patients.
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Oct 4, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the reasons why some transgender patients choose to preserve their ability to have children, while others do not. The researchers want to understand the differences between those who decide to take steps to protect their fertility and those who don’t. The study also aims to find out how many transgender patients are interested in becoming parents in the future.
To participate in this study, individuals must be transgender patients who visited the Assisted Reproductive Technology center at the Nancy Regional University Hospital between January 2020 and June 2023, either for starting their transition, follow-up care, or to discuss parenting. Unfortunately, minors and individuals under guardianship are not eligible. Participants can expect that their routine medical records will be reviewed to gather information for the study, but there will be no direct interaction or intervention as part of the trial. This research is important as it may help improve support and resources for transgender individuals who wish to preserve their fertility.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Transgender patients who consulted the Assisted Reproductive Technology centre of the Nancy Regional University Hospital, between 1st January 2020 and 30th June 2023. The consultations occurred for the start of transition care, for follow-up or for a parenting project for transgender patients.
- Exclusion Criteria:
- • minors
- • patients under guardianship or under tutelage
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nancy, , France
Patients applied
Trial Officials
Mikael AGOPIANTZ, PHD MCU
Principal Investigator
CentralHNF Nancy Regional University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported